Global Life Science Business Partnering (GLSBP) - March 2022

Highlights of March 2022

  1. Aurobindo Pharma acquires Veritaz formulation biz for Rs 171 crores (~US$23M).
  2. Alembic Pharma acquires 100% stake in Aleor Dermaceuticals.
  3. SunPharma to acquire Daiichi's 11.28% stake in Zenotech
  4. Sun Pharma entered into an exclusive patent licensing agreement with Denmark-based H Lundbeck (Lundbeck) to market and distribute its version of Vortioxetine.
  5. Sentynl Therapeutics, a US biopharmaceutical company and a wholly owned subsidiary of Zydus Lifesciences announced the execution of an asset purchase agreement for the sale of BridgeBio’s NULIBRY (Fosdenopterin) for injection.
  6. Strides Pharma, Medicines Patent Pool to commercialize Pfizer's generic COVID-19 oral drug.
  7. TTK Healthcare to sell human pharma biz to Bharat Serums.
  8. Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data.
  9. Eagle Pharmaceuticals signs deal to acquire UK-based Acacia Pharma
  10. Bavarian Nordic enters license and supply agreement with Nuance Pharma.
  11. Grünenthal links up with NovaQuest to advance development of resiniferatoxin.
  12. Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets.

Highlights at Aagami:

  1. New Client Win: Aagami has bagged an assignment to supporting Licensing/Investments for an Israel based revolutionary solution in IVF treatment.
  2. Contract Extension: Aagami received contract extension from 2 clients
  3. BIO International Convention partnering system opens early April 2022. Our meeting calendar opens same time. We welcome any request to meet in San Diego.

INFOCUS: Select opportunities available at Aagami:

For Acquisition:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, IP etc.- for Next-generation biologics and substantial returns. Available at a very reasonable price.

For Partnering/Licensing/ Investment:

  1. Investment in the US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications. Extended Series B note with discount on Series C available for a very limited time.
  2. Licensing/Strategic Partnership: Next-gen AI powered imaging to pinpoint the IVF 24 hour window of opportunity to implant the embryo. First solution that supports the science of uterine receptivity vs. a physician's estimates or inaccurate ultrasound. Market Launch early 2024.
  3. Seeking $7M Bridge to Series B (Over $5M fully committed) - Novel Evolution of Portable MRI and Robotics for Strokes and TBI. Total of $7.8M has been Raised so far. Series B will open shortly.
  4. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
  5. Licensing, Co-development - 505(b)(2) low cost near market IP protected Bendamustine. Negligible competition(3) in the ~$500M US market.
  6. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
  7. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
  8. Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
×
Twitter